<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Epstein-Barr virus (EBV) nuclear antigen EBNA1 is the only <z:mp ids='MP_0001799'>viral</z:mp> protein detectably expressed in virus genome-positive Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>); recent work has suggested that <z:mp ids='MP_0001799'>viral</z:mp> strains with particular EBNA1 sequence changes are preferentially associated with this <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and that, within a patient, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated variant may have arisen de novo as a rare mutant of the dominant preexisting EBV strain (K </plain></SENT>
<SENT sid="1" pm="."><plain>Bhatia, A </plain></SENT>
<SENT sid="2" pm="."><plain>Raj, M </plain></SENT>
<SENT sid="3" pm="."><plain>J </plain></SENT>
<SENT sid="4" pm="."><plain>Gutierrez, J </plain></SENT>
<SENT sid="5" pm="."><plain>G </plain></SENT>
<SENT sid="6" pm="."><plain>Judde, G </plain></SENT>
<SENT sid="7" pm="."><plain>Spangler, H </plain></SENT>
<SENT sid="8" pm="."><plain>Venkatesh, and I </plain></SENT>
<SENT sid="9" pm="."><plain>T </plain></SENT>
<SENT sid="10" pm="."><plain>Magrath, Oncogene 13:177-181, 1996) </plain></SENT>
<SENT sid="11" pm="."><plain>In the present work we first study 12 BL patients and show that the virus strain in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> is identical in EBNA1 sequence and that it is matched at several other polymorphic loci to the dominant strain rescued in vitro from the patient's <z:mpath ids='MPATH_458'>normal</z:mpath> circulating B cells </plain></SENT>
<SENT sid="12" pm="."><plain>We then analyze <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-associated virus strains from three different geographic areas (East Africa, Europe, and New Guinea) alongside virus isolates from geographically matched control donors by using sequence changes in two separate regions of the EBNA1 gene (N-terminal codons 1 to 60 and C-terminal codons 460 to 510) to identify the EBNA1 subtype of each virus </plain></SENT>
<SENT sid="13" pm="."><plain>Different geographic areas displayed different spectra of EBNA1 subtypes, with only limited overlap between them; even type 2 virus strains, which tended to be more homogeneous than their type 1 counterparts, showed geographic differences at the EBNA1 locus </plain></SENT>
<SENT sid="14" pm="."><plain>Most importantly, within any one area the EBNA1 subtypes associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> were also found to be prevalent in the general population </plain></SENT>
<SENT sid="15" pm="."><plain>We therefore find no evidence that Burkitt <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> involves a selection for EBV strains with particular EBNA1 sequence changes </plain></SENT>
</text></document>